Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$1.13
+0.9%
$1.11
$0.80
$3.08
$46.43M-1.1218,524 shs3,081 shs
DURECT Co. stock logo
DRRX
DURECT
$0.50
-8.1%
$0.70
$0.49
$1.88
$15.52M0.6688,809 shs248,125 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$13.37
+5.6%
$13.41
$5.22
$27.38
$168.30M0.41142,129 shs173,215 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.03
-11.3%
$0.03
$0.02
$6.93
$741K1.318.06 million shs382,223 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
+0.89%+11.87%-0.88%-8.13%-46.70%
DURECT Co. stock logo
DRRX
DURECT
-8.11%-18.06%-25.34%-37.50%-61.55%
LifeVantage Co. stock logo
LFVN
LifeVantage
+5.61%+0.91%+9.05%-21.72%+77.56%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-11.25%-7.69%-13.75%-82.03%-99.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.8758 of 5 stars
3.55.00.00.03.31.70.0
DURECT Co. stock logo
DRRX
DURECT
0.6342 of 5 stars
0.01.00.04.42.20.00.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.812 of 5 stars
3.51.01.72.71.61.71.3
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.0264 of 5 stars
3.10.00.04.30.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
3.00
Buy$5.50386.73% Upside
DURECT Co. stock logo
DRRX
DURECT
2.00
HoldN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50128.12% Upside
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.20
Hold$3.3311,977.29% Upside

Current Analyst Ratings Breakdown

Latest DRRX, SYRS, LFVN, and ANEB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $3.00
3/27/2025
DURECT Co. stock logo
DRRX
DURECT
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
DURECT Co. stock logo
DRRX
DURECT
$1.86M8.36N/AN/A$0.50 per share1.00
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.76$0.70 per share19.03$2.38 per share5.62
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K1.92N/AN/A$0.79 per share0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.26N/AN/AN/A-119.54%-108.08%N/A
DURECT Co. stock logo
DRRX
DURECT
-$27.62M-$0.15N/AN/AN/A-198.58%-300.62%-65.17%8/12/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6923.88N/A3.46%34.29%15.04%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%6/2/2025 (Estimated)

Latest DRRX, SYRS, LFVN, and ANEB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05-$0.04+$0.01-$0.04N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/26/2025Q4 2024
DURECT Co. stock logo
DRRX
DURECT
$0.06-$0.06-$0.12$0.24$6.91 million$2.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
DURECT Co. stock logo
DRRX
DURECT
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.35%N/A26.09%3 Years
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A

Latest DRRX, SYRS, LFVN, and ANEB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
17.51
17.51
DURECT Co. stock logo
DRRX
DURECT
N/A
0.71
0.60
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
DURECT Co. stock logo
DRRX
DURECT
28.03%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
DURECT Co. stock logo
DRRX
DURECT
3.20%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.09 million5.79 millionNot Optionable
DURECT Co. stock logo
DRRX
DURECT
8031.04 million30.05 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12026.83 million23.54 millionOptionable

Recent News About These Companies

Syros Pharmaceuticals trading resumes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.13 +0.01 (+0.89%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.13 0.00 (0.00%)
As of 05/27/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

DURECT stock logo

DURECT NASDAQ:DRRX

$0.50 -0.04 (-8.11%)
As of 05/27/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$13.37 +0.71 (+5.61%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$13.16 -0.21 (-1.60%)
As of 05/27/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.03 0.00 (-11.25%)
As of 05/27/2025 03:25 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.